Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
|
| gptkbp:activeIngredient |
gptkb:ceftaroline_fosamil
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:European_Medicines_Agency 2010 |
| gptkbp:ATCCode |
J01DI02
|
| gptkbp:brand |
gptkb:ceftaroline_fosamil
|
| gptkbp:drugClass |
cephalosporin
|
| gptkbp:effect |
gptkb:methicillin-resistant_Staphylococcus_aureus
|
| gptkbp:form |
powder for solution for infusion
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zinforo
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:spectrumOfActivity |
Gram-negative bacteria
Gram-positive bacteria |
| gptkbp:usedFor |
bacterial infections
community-acquired pneumonia acute bacterial skin and skin structure infections |
| gptkbp:bfsParent |
gptkb:AstraZeneca_US
|
| gptkbp:bfsLayer |
6
|